Published: March 2, 2026 at 8:21 am
The new CEO of Oxford Nanopore Technologies has begun work today as he takes over from founder Gordon Sanghera.
Francis Van Parys will now lead the FTSE 250 MedTech, which is eyeing profitability after also reporting its results for 2025.
The DNA sequencing specialist reported revenues of £223.9 million, up 22.2% year-on-year, while adjusted EBITDA losses shrank 31.2% to £86.7m. Actual losses shrank 1% to £145.2m.
The firm reaffirmed its commitment to reach adjusted EBITDA breakeven in FY27 and become cash flow positive in FY28.
A trial has been set for 2027 for IP infringement against its products, while separately it has issued proceedings in the High Court alleging trade secrets infringement against the same defendant.